These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3354574)

  • 1. Microcytic anemia in dialysis patients.
    Grossman SD; Smith LE
    Am J Kidney Dis; 1988 Apr; 11(4):362. PubMed ID: 3354574
    [No Abstract]   [Full Text] [Related]  

  • 2. Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity.
    Swartz R; Dombrouski J; Burnatowska-Hledin M; Mayor G
    Am J Kidney Dis; 1987 Mar; 9(3):217-23. PubMed ID: 3826071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of an erythrocyte aluminum assay in the diagnosis of aluminum-associated microcytic anemia in patients undergoing dialysis and response to deferoxamine therapy.
    Abreo K; Brown ST; Sella M; Trapp G
    J Lab Clin Med; 1989 Jan; 113(1):50-7. PubMed ID: 2909650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of anemia with deferoxamine in hemodialysis patients with aluminum-induced bone disease.
    Tielemans C; Collart F; Wens R; Smeyers-Verbeeke J; van Hooff I; Dratwa M; Verbeelen D
    Clin Nephrol; 1985 Nov; 24(5):237-41. PubMed ID: 4075595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desferrioxamine improves anaemia in haemodialysis patients without aluminum or iron overload.
    Cuvelier R; Deceuninck P
    Nephrol Dial Transplant; 1988; 3(1):104. PubMed ID: 3132631
    [No Abstract]   [Full Text] [Related]  

  • 6. Desferrioxamine versus erythropoietin for treatment of dialysis anaemia.
    Padovese P; Gallieni M; Galmozzi C; Brancaccio D
    Lancet; 1990 Jun; 335(8703):1465. PubMed ID: 1972238
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of desferrioximine in dialysis-associated aluminium disease.
    Ackrill P; Day JP
    Contrib Nephrol; 1993; 102():125-34. PubMed ID: 8416177
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of desferrioxamine on anaemia of haemodialysis patients.
    Felipe C; Rivera M; Orofino L; Matesanz R; Ortuño J
    Nephrol Dial Transplant; 1988; 3(1):105-106. PubMed ID: 3132633
    [No Abstract]   [Full Text] [Related]  

  • 9. Desferrioxamine, anaemia, and haemodialysis.
    Lancet; 1988 Jun; 1(8599):1405-6. PubMed ID: 2898087
    [No Abstract]   [Full Text] [Related]  

  • 10. Deferoxamine use in aluminum toxicity.
    Lewis M; Lesniak S
    ANNA J; 1986 Aug; 13(4):210-1. PubMed ID: 3638947
    [No Abstract]   [Full Text] [Related]  

  • 11. Aluminum kinetics of the REDY system: a study of the impact of deferoxamine therapy.
    Culpepper CP; Cummings R; Westervelt FB; Savory J; Wills MR
    Trans Am Soc Artif Intern Organs; 1983; 29():76-80. PubMed ID: 6673321
    [No Abstract]   [Full Text] [Related]  

  • 12. [Aluminum and iron deposition in dialysis patients].
    Kurihara S; Marumo F
    Nihon Rinsho; 1992 Jan; 50 Suppl():905-10. PubMed ID: 1578787
    [No Abstract]   [Full Text] [Related]  

  • 13. Intraperitoneal deferoxamine therapy for aluminum intoxication in a child undergoing continuous ambulatory peritoneal dialysis.
    Andreoli SP; Dunn D; DeMyer W; Sherrard DJ; Bergstein JM
    J Pediatr; 1985 Nov; 107(5):760-3. PubMed ID: 3932629
    [No Abstract]   [Full Text] [Related]  

  • 14. Desferrioxamine does not improve aluminium-unrelated anaemia of haemodialysis.
    Basile C; Scatizzi A
    Nephrol Dial Transplant; 1988; 3(3):355. PubMed ID: 3140114
    [No Abstract]   [Full Text] [Related]  

  • 15. Deferoxamine for aluminum toxicity in dialysis patients.
    Hernandez P; Johnson CA
    ANNA J; 1990 Jun; 17(3):224-8. PubMed ID: 2357118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prurigo nodularis and aluminium overload in maintenance haemodialysis.
    Brown MA; George CR; Dunstan CR; Kalowski S; Corrigan AB
    Lancet; 1992 Jul; 340(8810):48. PubMed ID: 1351616
    [No Abstract]   [Full Text] [Related]  

  • 17. Recognition and management of aluminum intoxication in children.
    Tsuru N; Williams JL; Chan JC
    Int J Pediatr Nephrol; 1987; 8(3):177-86. PubMed ID: 3323095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aluminum, vanadium, and lead intoxication of uremic patients undergoing hemodialysis in Venezuela.
    Romero RA
    Transplant Proc; 1994 Feb; 26(1):330-2. PubMed ID: 8109003
    [No Abstract]   [Full Text] [Related]  

  • 19. Hyperparathyroidism after aluminum depletion.
    Almirall J; Campistol JM; Torras A; Revert L
    Nephron; 1990; 55(1):94-5. PubMed ID: 2352586
    [No Abstract]   [Full Text] [Related]  

  • 20. Anaemia and aluminium chelation therapy in dialysis patients.
    Tielemans C; Collart F; Wens R; Smeyers-Verbeeke J; Van Hooff I; Dratwa M; Verbeelen D
    Lancet; 1988 Jul; 2(8604):220. PubMed ID: 2899690
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.